DOCSLIB.ORG

Biological Pathways, Candidate Genes, and Molecular Markers Associated with Quality-Of-Life Domains: an Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biological Pathways, Candidate Genes, and Molecular Markers Associated with Quality-Of-Life Domains: an Update Qual Life Res DOI 10.1007/s11136-014-0656-1 REVIEW Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update Mirjam A. G. Sprangers • Melissa S. Y. Thong • Meike Bartels • Andrea Barsevick • Juan Ordon˜ana • Qiuling Shi • Xin Shelley Wang • Pa˚l Klepstad • Eddy A. Wierenga • Jasvinder A. Singh • Jeff A. Sloan Accepted: 19 February 2014 Ó Springer International Publishing Switzerland 2014 Abstract (depressed mood) and positive (well-being/happiness) Background There is compelling evidence of a genetic emotional functioning, social functioning, and overall foundation of patient-reported quality of life (QOL). Given QOL. the rapid development of substantial scientific advances in Methods We followed a purposeful search algorithm of this area of research, the current paper updates and extends existing literature to capture empirical papers investigating reviews published in 2010. the relationship between biological pathways and molecu- Objectives The objective was to provide an updated lar markers and the identified QOL domains. overview of the biological pathways, candidate genes, and Results Multiple major pathways are involved in each molecular markers involved in fatigue, pain, negative QOL domain. The inflammatory pathway has the strongest evidence as a controlling mechanism underlying fatigue. Inflammation and neurotransmission are key processes On behalf of the GeneQol Consortium. involved in pain perception, and the catechol-O-methyl- transferase (COMT) gene is associated with multiple sorts Electronic supplementary material The online version of this article (doi:10.1007/s11136-014-0656-1) contains supplementary of pain. The neurotransmitter and neuroplasticity theories material, which is available to authorized users. M. A. G. Sprangers (&) Á M. S. Y. Thong P. Klepstad Department of Medical Psychology/J3-211, Academic Medical Chair Department of Intensive Care Medicine, St. Olav Center, University of Amsterdam, Meibergdreef 15, University Hospital, Trondheim, Norway 1105 AZ Amsterdam, The Netherlands e-mail: [email protected] E. A. Wierenga Department of Cell Biology and Histology, Academic Medical M. S. Y. Thong Center, University of Amsterdam, Amsterdam, The Netherlands Center of Research on Psychology in Somatic diseases (CoRPS), Tilburg University, Tilburg, The Netherlands J. A. Singh Birmingham VA Medical Center, University of Alabama at M. Bartels Birmingham, Birmingham, AL, USA Department of Biological Psychology, VU University, Amsterdam, The Netherlands J. A. Singh Mayo Clinic College of Medicine, Rochester, MN, USA A. Barsevick Thomas Jefferson University, Philadelphia, PA, USA J. A. Sloan Section of Cancer Center Statistics, Division of Biomedical J. Ordon˜ana Statistics and Informatics, Department of Health Sciences, Mayo Department of Human Anatomy and Psychobiology, University Clinic, Rochester, MN, USA of Murcia, Murcia, Spain Q. Shi Á X. S. Wang Department of Symptom Research, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA 123 Qual Life Res have the strongest evidence for their relationship with computerized literature search on PubMed for the years depression. Oxytocin-related genes and genes involved in November 2007–November 2012. However, we did not set a the serotonergic and dopaminergic pathways play a role in limitation on year of publication for overall QOL as the social functioning. Inflammatory pathways, via cytokines, GeneQol Consortium had not previously published a review also play an important role in overall QOL. on this subject. Due to the large number of hits on depression Conclusions Whereas the current findings need future and pain, up-to-date publications were limited to the last experiments and replication efforts, they will provide three years (2010–2012). Articles or book chapters found researchers supportive background information when through reference checking or personal communication embarking on studies relating candidate genes and/or (until June, 2013) were also included. molecular markers to QOL domains. The ultimate goal of Specific search terms are provided as supplementary this area of research is to enhance patients’ QOL. material (see Supplementary information 1). Empirical papers investigating the relationship between biological pathways/ Keywords Biological pathways Á Genes Á Molecular molecular markers and the following QOL domains were markers Á Quality of life Á Patient-reported outcomes included: fatigue, pain, emotional functioning (depression, (PROs) well-being/happiness), social functioning, and overall QOL. We limited our search to publications in English on human subjects. Introduction A gene or molecular marker is included if there is at least one publication (either empirical, meta-analysis or In 2004, empirical support was found for the provocative review) reporting its significant association with a QOL hypothesis that there is a genetic basis to patient-reported domain. The findings are provided in Tables 1, 2, 3, 4, 5, quality of life (QOL) [1]. In response to this preliminary and 6 for each QOL domain, respectively. References work [2], an international and interdisciplinary research included in the tables are provided as supplementary consortium (GeneQol) was formed to set out the state of information. The text will only elaborate on new infor- the science at that point and to design and implement a mation since our previous reviews. program of research [3]. A theoretical framework was The primary source for identifying the biological path- published to facilitate and focus the investigation into the ways was the KEGG website (Kyoto Encyclopedia for Genes biological foundation of self-perceived QOL [4]. and Genomes) (http://www.genome.jp/kegg/) and supple- Multiple publications and studies ensued laying the mented by Genecards website (http://www.genecards.org/). groundwork for methodological approaches and identifying candidate molecular markers, e.g., [5–7]. Replication of preliminary work has been seen alongside new markers [8]. Results Reviews documented the biological pathways and molecular markers that were found to be associated with QOL domains, Fatigue including the most prevalent symptoms pain [9] and fatigue [10], and emotional [11] and social functioning [12]. To the best of our knowledge, no genome-wide association As a result of this collective work, there is now com- studies (GWAS) on fatigue have been published to date. pelling evidence of a genetic foundation of QOL. Given the Several biological pathways show promise as underlying rapid development of substantial scientific advances in this mechanisms of fatigue: inflammation, serotonin, dopamine, area of research, the current paper updates and extends the and glutathione metabolic pathways [10, 13]. previous work. The objective was to provide an updated Saligan [14] synthesized the evidence for inflammatory overview of the biological pathways, candidate genes, and pathway involvement. In cross-sectional studies, various molecular markers for these domains and those for overall markers of immunity and inflammation obtained at various QOL. This information will provide researchers supportive time points from blood, plasma, serum or in vitro were background information when embarking on studies relat- inconsistent in predicting fatigue depending on the covar- ing candidate genes and/or molecular markers to QOL. iates included in the analysis [15]. In a small number of longitudinal studies, primarily in women with early-stage breast cancer, fatigue was associated with elevations in Methods immune response and inflammation. Significant associa- tions have also been demonstrated between fatigue and To provide an overview of the state of the science, we started genomic markers. Higher morning and evening fatigue in by including the references provided in our earlier reviews cancer patients and caregivers was found to be related to [2, 3, 9–12]. To update these references, we conducted a single nucleotide polymorphisms (SNPs) of the interleukin 123 Qual Life Res Table 1 Biological pathways, candidate genes, and molecular markers in fatigue Quality-of-life domains Biological pathwaysa Candidate genes Molecular markers Literature Fatigue [1] Serotonergic synapse/ TPH1 5-HT [2–5] metabolic pathway Dopaminergic synapse COMT, DRD4, DAT1 Cortisol [6, 7] Glutathione metabolic GSTZ1, ABCC4, DPYD, GSTP1, NR [8–10] pathway OPRT/UMPS Inflammation Cytokine–cytokine [11] receptor interaction Pro-inflammatory IL-1b,IL-6, TNF-a, CD19?b IL-1b, IL-6, TNF-a, [12–25] CD19?b, TNF-R1, Anti-inflammatory IL-1RN, IL-1Ra,IL-10 IL-1RN, IL-1Ra, IL-10 [13–15, 17] Immunity IL-2, IL-4, IL-5, IFN-c IL-2, IL-4, IL-5, IFN-c [12, 26] Cell migration CXCL9, CXCL11 CXCL9, CXCL11 [27] Inflammation CRP CRP, neopterin [4, 13] Cortisol production, serotonin HPA NR CRH, ACTH, cortisol, [28–31] dysregulation, catecholamine melatonin, norepinephrine, epinephrine Circadian rhythm disruption—i.e., SCN PER2, PER3, TIMELESS EGF, TGF-a, neuregulin-1, [28, through modulation of arousal and prokineticine-2, 32–37] sleep patterns cardiotrophin-like cytokine, PER2, PER3, cortisol, melatonin EGFR NR NR [28] Peripheral fatigue (muscle strength) Skeletal muscle NR ATP [37, 38] Vagal afferent nerve activation Cytokine–cytokine (suppress somatic muscle receptor interaction activity—‘sickness Pro-inflammatory IL-1, IL-6, TNF-a IL-1, IL-6, TNF-a [39] behavior’) References are included in Supplementary Material 2: References to Tables 1–7 a Biological pathways are according to KEGG
Load more

Recommended publications
  • Nuclear and Mitochondrial Genome Defects in Autisms
    UC Irvine UC Irvine Previously Published Works Title Nuclear and mitochondrial genome defects in autisms. Permalink https://escholarship.org/uc/item/8vq3278q Journal Annals of the New York Academy of Sciences, 1151(1) ISSN 0077-8923 Authors Smith, Moyra Spence, M Anne Flodman, Pamela Publication Date 2009 DOI 10.1111/j.1749-6632.2008.03571.x License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California THE YEAR IN HUMAN AND MEDICAL GENETICS 2009 Nuclear and Mitochondrial Genome Defects in Autisms Moyra Smith, M. Anne Spence, and Pamela Flodman Department of Pediatrics, University of California, Irvine, California In this review we will evaluate evidence that altered gene dosage and structure im- pacts neurodevelopment and neural connectivity through deleterious effects on synap- tic structure and function, and evidence that the latter are key contributors to the risk for autism. We will review information on alterations of structure of mitochondrial DNA and abnormal mitochondrial function in autism and indications that interactions of the nuclear and mitochondrial genomes may play a role in autism pathogenesis. In a final section we will present data derived using Affymetrixtm SNP 6.0 microar- ray analysis of DNA of a number of subjects and parents recruited to our autism spectrum disorders project. We include data on two sets of monozygotic twins. Col- lectively these data provide additional evidence of nuclear and mitochondrial genome imbalance in autism and evidence of specific candidate genes in autism. We present data on dosage changes in genes that map on the X chromosomes and the Y chro- mosome.
    [Show full text]
  • Urocortin 3 Overexpression Reduces ER Stress and Heat Shock Response in 3T3‑L1 Adipocytes Sina Kavalakatt1, Abdelkrim Khadir1, Dhanya Madhu1, Heikki A
    www.nature.com/scientificreports OPEN Urocortin 3 overexpression reduces ER stress and heat shock response in 3T3‑L1 adipocytes Sina Kavalakatt1, Abdelkrim Khadir1, Dhanya Madhu1, Heikki A. Koistinen2,3,4, Fahd Al‑Mulla5, Jaakko Tuomilehto4,6, Jehad Abubaker1 & Ali Tiss 1* The neuropeptide urocortin 3 (UCN3) has a benefcial efect on metabolic disorders, such as obesity, diabetes, and cardiovascular disease. It has been reported that UCN3 regulates insulin secretion and is dysregulated with increasing severity of obesity and diabetes. However, its function in the adipose tissue is unclear. We investigated the overexpression of UCN3 in 3T3‑L1 preadipocytes and diferentiated adipocytes and its efects on heat shock response, ER stress, infammatory markers, and glucose uptake in the presence of stress‑inducing concentrations of palmitic acid (PA). UCN3 overexpression signifcantly downregulated heat shock proteins (HSP60, HSP72 and HSP90) and ER stress response markers (GRP78, PERK, ATF6, and IRE1α) and attenuated infammation (TNFα) and apoptosis (CHOP). Moreover, enhanced glucose uptake was observed in both preadipocytes and mature adipocytes, which is associated with upregulated phosphorylation of AKT and ERK but reduced p‑JNK. Moderate efects of UCN3 overexpression were also observed in the presence of 400 μM of PA, and macrophage conditioned medium dramatically decreased the UCN3 mRNA levels in diferentiated 3T3‑L1 cells. In conclusion, the benefcial efects of UCN3 in adipocytes are refected, at least partially, by the improvement in cellular
    [Show full text]
  • Endocrine Cell Type Sorting and Mature Architecture in the Islets Of
    www.nature.com/scientificreports OPEN Endocrine cell type sorting and mature architecture in the islets of Langerhans require expression of Received: 16 April 2018 Accepted: 4 July 2018 Roundabout receptors in β cells Published: xx xx xxxx Melissa T. Adams, Jennifer M. Gilbert, Jesus Hinojosa Paiz, Faith M. Bowman & Barak Blum Pancreatic islets of Langerhans display characteristic spatial architecture of their endocrine cell types. This architecture is critical for cell-cell communication and coordinated hormone secretion. Islet architecture is disrupted in type-2 diabetes. Moreover, the generation of architecturally correct islets in vitro remains a challenge in regenerative approaches to type-1 diabetes. Although the characteristic islet architecture is well documented, the mechanisms controlling its formation remain obscure. Here, we report that correct endocrine cell type sorting and the formation of mature islet architecture require the expression of Roundabout (Robo) receptors in β cells. Mice with whole-body deletion of Robo1 and conditional deletion of Robo2 either in all endocrine cells or selectively in β cells show complete loss of endocrine cell type sorting, highlighting the importance of β cells as the primary organizer of islet architecture. Conditional deletion of Robo in mature β cells subsequent to islet formation results in a similar phenotype. Finally, we provide evidence to suggest that the loss of islet architecture in Robo KO mice is not due to β cell transdiferentiation, cell death or loss of β cell diferentiation or maturation. Te islets of Langerhans display typical, species-specifc architecture, with distinct spatial organization of their various endocrine cell types1–5. In the mouse, the core of the islet is composed mostly of insulin-secreting β cells, while glucagon-secreting α cells, somatostatin-secreting δ cells and pancreatic polypeptide-secreting PP cells are located at the islet periphery3.
    [Show full text]
  • UC Davis UC Davis Previously Published Works
    UC Davis UC Davis Previously Published Works Title Cardiac CRFR1 Expression Is Elevated in Human Heart Failure and Modulated by Genetic Variation and Alternative Splicing. Permalink https://escholarship.org/uc/item/8r73t67n Journal Endocrinology, 157(12) ISSN 0013-7227 Authors Pilbrow, Anna P Lewis, Kathy A Perrin, Marilyn H et al. Publication Date 2016-12-01 DOI 10.1210/en.2016-1448 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Manuscript (MUST INCLUDE TITLE PAGE AND ABSTRACT) Click here to download Manuscript (MUST INCLUDE TITLE PAGE AND ABSTRACT) Endocrinology CRFR1 ms.docx 1 Myocardial expression of Corticotropin-Releasing Factor Receptor 1 (CRFR1) is elevated in human 2 heart failure and is modulated by genetic variation and a novel CRFR1 splice variant. 3 4 Anna P Pilbrow1,2,* PhD, Kathy A Lewis1 BS, Marilyn H Perrin1 PhD, Wendy E Sweet3 MS, Christine S 5 Moravec3 PhD, WH Wilson Tang3 MD, Mark O Huising1 PhD, Richard W Troughton2 MD PhD and 6 Vicky A Cameron2 PhD. 7 8 1. Peptide Biology Laboratories, The Salk Institute for Biological Studies, 10010 North Torrey Pines 9 Road, La Jolla, CA 92037, USA. 10 2. Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, 2 11 Riccarton Avenue, PO Box 4345, Christchurch 8011, New Zealand. 12 3. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 13 Euclid Avenue, Cleveland, OH 44195, USA. 14 15 Abbreviated title: CRFR1 in human heart failure 16 Keywords: heart failure, CRFR1, CRHR1, alternative splicing, splice variant, polymorphism, human.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Genetic Drivers of Pancreatic Islet Function
    | INVESTIGATION Genetic Drivers of Pancreatic Islet Function Mark P. Keller,*,1 Daniel M. Gatti,†,1 Kathryn L. Schueler,* Mary E. Rabaglia,* Donnie S. Stapleton,* Petr Simecek,† Matthew Vincent,† Sadie Allen,‡ Aimee Teo Broman,§ Rhonda Bacher,§ Christina Kendziorski,§ Karl W. Broman,§ Brian S. Yandell,** Gary A. Churchill,†,2 and Alan D. Attie*,2 *Department of Biochemistry, §Department of Biostatistics and Medical Informatics, and **Department of Horticulture, University of Wisconsin–Madison, Wisconsin 53706-1544, †The Jackson Laboratory, Bar Harbor, Maine 06409, and ‡Maine School of Science and Mathematics, Limestone, Maine 06409, ORCID IDs: 0000-0002-7405-5552 (M.P.K.); 0000-0002-4914-6671 (K.W.B.); 0000-0001-9190-9284 (G.A.C.); 0000-0002-0568-2261 (A.D.A.) ABSTRACT The majority of gene loci that have been associated with type 2 diabetes play a role in pancreatic islet function. To evaluate the role of islet gene expression in the etiology of diabetes, we sensitized a genetically diverse mouse population with a Western diet high in fat (45% kcal) and sucrose (34%) and carried out genome-wide association mapping of diabetes-related phenotypes. We quantified mRNA abundance in the islets and identified 18,820 expression QTL. We applied mediation analysis to identify candidate causal driver genes at loci that affect the abundance of numerous transcripts. These include two genes previously associated with monogenic diabetes (PDX1 and HNF4A), as well as three genes with nominal association with diabetes-related traits in humans (FAM83E, IL6ST, and SAT2). We grouped transcripts into gene modules and mapped regulatory loci for modules enriched with transcripts specific for a-cells, and another specific for d-cells.
    [Show full text]
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • Piccolo, a Presynaptic Zinc Finger Protein Structurally Related to Bassoon
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Neuron, Vol. 25, 203±214, January, 2000, Copyright 2000 by Cell Press Piccolo, a Presynaptic Zinc Finger Protein Structurally Related to Bassoon Steven D. Fenster,*# Wook Joon Chung,*# presynaptic cytoskeletal matrix (PCM) (Landis et al., Rong Zhai,*# Claudia Cases-Langhoff,*# Britta Voss,² 1988; Hirokawa et al., 1989; Gotow et al., 1991) that is Abigail M. Garner,² Udo Kaempf,§ Stefan Kindler,³ thought to play a role in maintaining the neurotransmitter § Eckart D. Gundelfinger, and Craig C. Garner*k release site in register with the postsynaptic reception *Department of Neurobiology apparatus, regulating the mobilization of SVs and the University of Alabama at Birmingham refilling of release sites. Mechanistically, the PCM may Birmingham, Alabama 35294 define sites where SVs fuse and recycle through the ² Center for Molecular Neurobiology clustering of the exo- and endocytotic machinery. ³ Institute for Cellular Biochemistry SV cycling is a multistep process that involves vesicle and Clinical Neurobiology mobilization from a reserve pool, docking at active University of Hamburg zones, and calcium-dependent fusion (SuÈ dhof, 1995; D-20246 Hamburg Hanson et al., 1997). The latter two steps require the § Leibniz Institute for Neurobiology formation of a complex composed of the vesicle SNARE D-39118 Magdeburg VAMP2/Synaptobrevin and two target SNAREs, syn- Federal Republic of Germany taxin and SNAP-25 (SuÈ dhof, 1995; Hanson et al., 1997). In addition, a family of low molecular weight GTPases are likely to be involved in SV cycling with rab3 and rab5 Summary regulating exocytotic and endocytotic events, respec- tively (Ferro-Novick and Novick, 1993; Hess et al., 1993; Piccolo is a novel component of the presynaptic cy- SuÈ dhof, 1995).
    [Show full text]
  • Targeted Pharmacological Therapy Restores Β-Cell Function for Diabetes Remission
    Targeted pharmacological therapy restores -cell function for diabetes remission Sachs, Stephan; Bastidas-Ponce, Aimée; Tritschler, Sophie; Bakhti, Mostafa; Böttcher, Anika; Sánchez-Garrido, Miguel A; Tarquis-Medina, Marta; Kleinert, Maximilian; Fischer, Katrin; Jall, Sigrid; Harger, Alexandra; Bader, Erik; Roscioni, Sara; Ussar, Siegfried; Feuchtinger, Annette; Yesildag, Burcak; Neelakandhan, Aparna; Jensen, Christine B; Cornu, Marion; Yang, Bin; Finan, Brian; DiMarchi, Richard D; Tschöp, Matthias H; Theis, Fabian J; Hofmann, Susanna M.; Müller, Timo D; Lickert, Heiko Published in: Nature Metabolism DOI: 10.1038/s42255-020-0171-3 Publication date: 2020 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Sachs, S., Bastidas-Ponce, A., Tritschler, S., Bakhti, M., Böttcher, A., Sánchez-Garrido, M. A., Tarquis-Medina, M., Kleinert, M., Fischer, K., Jall, S., Harger, A., Bader, E., Roscioni, S., Ussar, S., Feuchtinger, A., Yesildag, B., Neelakandhan, A., Jensen, C. B., Cornu, M., ... Lickert, H. (2020). Targeted pharmacological therapy restores - cell function for diabetes remission. Nature Metabolism, 2(2), 192-209. https://doi.org/10.1038/s42255-020- 0171-3 Download date: 05. Oct. 2021 ARTICLES https://doi.org/10.1038/s42255-020-0171-3 There are amendments to this paper Targeted pharmacological therapy restores β-cell function for diabetes remission Stephan Sachs1,2,3,4,19, Aimée Bastidas-Ponce1,4,5,6,19, Sophie Tritschler1,4,7,8,19, Mostafa Bakhti 1,4,5, Anika Böttcher1,4,5, Miguel A. Sánchez-Garrido2, Marta Tarquis-Medina1,4,5,6, Maximilian Kleinert2,9, Katrin Fischer2,3, Sigrid Jall2,3, Alexandra Harger2, Erik Bader1, Sara Roscioni1, Siegfried Ussar 4,6,10, Annette Feuchtinger11, Burcak Yesildag12, Aparna Neelakandhan12, Christine B.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Prioritization of Metabolic Genes As Novel Therapeutic Targets in Estrogen-Receptor Negative Breast Tumors Using Multi-Omics Data and Text Mining
    www.oncotarget.com Oncotarget, 2019, Vol. 10, (No. 39), pp: 3894-3909 Research Paper Prioritization of metabolic genes as novel therapeutic targets in estrogen-receptor negative breast tumors using multi-omics data and text mining Dinesh Kumar Barupal1,*, Bei Gao1,*, Jan Budczies2, Brett S. Phinney4, Bertrand Perroud4, Carsten Denkert2,3 and Oliver Fiehn1 1West Coast Metabolomics Center, University of California, Davis, CA, USA 2Institute of Pathology, Charité University Hospital, Berlin, Germany 3German Institute of Pathology, Philipps-University Marburg, Marburg, Germany 4UC Davis Genome Center, University of California, Davis, CA, USA *Co-first authors and contributed equally to this work Correspondence to: Oliver Fiehn, email: [email protected] Keywords: set-enrichment; ChemRICH; multi-omics; metabolic networks; candidate gene prioritization Received: March 12, 2019 Accepted: May 13, 2019 Published: June 11, 2019 Copyright: Barupal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Estrogen-receptor negative (ERneg) breast cancer is an aggressive breast cancer subtype in the need for new therapeutic options. We have analyzed metabolomics, proteomics and transcriptomics data for a cohort of 276 breast tumors (MetaCancer study) and nine public transcriptomics datasets using univariate statistics, meta- analysis, Reactome pathway analysis, biochemical network mapping and text mining of metabolic genes. In the MetaCancer cohort, a total of 29% metabolites, 21% proteins and 33% transcripts were significantly different (raw p <0.05) between ERneg and ERpos breast tumors.
    [Show full text]
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]